Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3K delta Immunomodulators.
Methot, J.L., Zhou, H., McGowan, M.A., Anthony, N.J., Christopher, M., Garcia, Y., Achab, A., Lipford, K., Trotter, B.W., Altman, M.D., Fradera, X., Lesburg, C.A., Li, C., Alves, S., Chappell, C.P., Jain, R., Mangado, R., Pinheiro, E., Williams, S.M.G., Goldenblatt, P., Hill, A., Shaffer, L., Chen, D., Tong, V., McLeod, R.L., Lee, H.H., Yu, H., Shah, S., Katz, J.D.(2021) J Med Chem 64: 5137-5156
- PubMed: 33797901 
- DOI: 10.1021/acs.jmedchem.1c00237
- Primary Citation of Related Structures:  
7LM2 - PubMed Abstract: 
The approvals of idelalisib and duvelisib have validated PI3Kδ inhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors with excellent isoform and kinome selectivity; however, they had high projected human doses ...